NASDAQ:FUSN

Fusion Pharmaceuticals News Headlines

$8.86
+0.16 (+1.84 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.57
$8.94
50-Day Range
$8.33
$12.15
52-Week Range
$8.09
$19.00
Volume11,164 shs
Average Volume47,211 shs
Market Capitalization$376.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Fusion Pharmaceuticals (NASDAQ FUSN) News Headlines Today

SourceHeadline
Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer StudyFusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study
finance.yahoo.com - May 6 at 4:57 PM
Fusion, Merck To Evaluate Fusions Targeted Alpha Therapy In Combination With Mercks KEYTRUDAFusion, Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA
nasdaq.com - May 6 at 11:57 AM
Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusions Targeted Alpha Therapy (TAT) in Combination with Mercks KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1RFusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R
finance.yahoo.com - May 6 at 11:57 AM
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Down 41.9% in AprilFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Short Interest Down 41.9% in April
americanbankingnews.com - April 30 at 4:46 PM
-$0.29 EPS Expected for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) This Quarter-$0.29 EPS Expected for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) This Quarter
americanbankingnews.com - April 30 at 10:37 AM
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Average Rating of "Buy" by AnalystsFusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - April 19 at 2:28 PM
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor ConferenceFusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 14 at 9:58 AM
Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target Cut to $21.00Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target Cut to $21.00
americanbankingnews.com - April 13 at 4:58 PM
-$0.29 Earnings Per Share Expected for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) This Quarter-$0.29 Earnings Per Share Expected for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) This Quarter
americanbankingnews.com - April 13 at 12:36 PM
Morgan Stanley Maintains Overweight on Fusion Pharmaceuticals, Lowers Price Target to $21Morgan Stanley Maintains Overweight on Fusion Pharmaceuticals, Lowers Price Target to $21
benzinga.com - April 7 at 2:02 PM
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of DirectorsFusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
finance.yahoo.com - April 1 at 9:31 AM
Are Insiders Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Stock?Are Insiders Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Stock?
finance.yahoo.com - March 26 at 9:42 AM
Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business UpdateFusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update
finance.yahoo.com - March 25 at 8:14 AM
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from IpsenFusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
finance.yahoo.com - March 2 at 7:45 AM
Fusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care ConferenceFusion Pharmaceuticals To Present At The Cowen 41st Annual Health Care Conference
finance.yahoo.com - February 23 at 5:42 PM
Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of DirectorsFusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors
finance.yahoo.com - February 11 at 9:04 AM
Fusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good Position To Deliver On Growth PlansFusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - January 25 at 8:04 AM
TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical IsotopeTRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope
finance.yahoo.com - December 16 at 11:40 AM
Is FUSN A Good Stock To Buy Now?Is FUSN A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 10:29 PM
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid TumorsFusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
finance.yahoo.com - December 10 at 8:26 AM
What Is The Ownership Structure Like For Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)?What Is The Ownership Structure Like For Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)?
finance.yahoo.com - November 26 at 7:34 AM
Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare ConferenceFusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 12 at 8:53 PM
Big things are Poppin at Bad Monkey Popcorn: Champlain Financial acquires rapidly expanding Canadian popcorn manufacturerBig things are Poppin' at Bad Monkey Popcorn: Champlain Financial acquires rapidly expanding Canadian popcorn manufacturer
finance.yahoo.com - November 12 at 3:53 PM
Fusion Pharmaceuticals EPS misses by $0.04Fusion Pharmaceuticals EPS misses by $0.04
seekingalpha.com - November 10 at 10:34 AM
Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business UpdateFusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update
finance.yahoo.com - November 10 at 10:34 AM
Fusion Pharmaceuticals Inc. Common Shares (FUSN)Fusion Pharmaceuticals Inc. Common Shares (FUSN)
nasdaq.com - November 2 at 5:11 PM
Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of DirectorsFusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors
finance.yahoo.com - November 2 at 5:11 PM
Orion Mine Finance Provides Update of its Ownership of Common Shares of Doré Copper Mining Corp.Orion Mine Finance Provides Update of its Ownership of Common Shares of Doré Copper Mining Corp.
finance.yahoo.com - October 27 at 5:21 PM
Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare ConferenceFusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
finance.yahoo.com - September 10 at 10:15 AM
Fusion Pharmaceuticals EPS of -$18.91Fusion Pharmaceuticals EPS of -$18.91
seekingalpha.com - August 11 at 4:26 PM
Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business UpdateFusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update
finance.yahoo.com - August 11 at 4:26 PM
Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceFusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 5 at 10:32 AM
FUSN Fusion Pharmaceuticals Inc. Common SharesFUSN Fusion Pharmaceuticals Inc. Common Shares
www.nasdaq.com - July 20 at 12:00 AM
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amountH1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
finance.yahoo.com - July 14 at 12:44 PM
Fc Fusion Protein Market Latest Trends 2020 Share, Top Key Players, Business Overview, Sales, Market Size, Revenue and Growth Rate Forecast to 2023Fc Fusion Protein Market Latest Trends 2020 Share, Top Key Players, Business Overview, Sales, Market Size, Revenue and Growth Rate Forecast to 2023
www.marketwatch.com - July 7 at 8:50 AM
BRIEF-Orbimed Advisors Reports Stake In Fusion Pharmaceuticals Of 7.2%BRIEF-Orbimed Advisors Reports Stake In Fusion Pharmaceuticals Of 7.2%
www.reuters.com - July 7 at 8:50 AM
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.